These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 23554889)

  • 1. Celastrol suppresses tumor cell growth through targeting an AR-ERG-NF-κB pathway in TMPRSS2/ERG fusion gene expressing prostate cancer.
    Shao L; Zhou Z; Cai Y; Castro P; Dakhov O; Shi P; Bai Y; Ji H; Shen W; Wang J
    PLoS One; 2013; 8(3):e58391. PubMed ID: 23554889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Function of phosphorylation of NF-kB p65 ser536 in prostate cancer oncogenesis.
    Zhang L; Shao L; Creighton CJ; Zhang Y; Xin L; Ittmann M; Wang J
    Oncotarget; 2015 Mar; 6(8):6281-94. PubMed ID: 25749044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer.
    Cai C; Wang H; He HH; Chen S; He L; Ma F; Mucci L; Wang Q; Fiore C; Sowalsky AG; Loda M; Liu XS; Brown M; Balk SP; Yuan X
    J Clin Invest; 2013 Mar; 123(3):1109-22. PubMed ID: 23426182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TMPRSS2-ERG fusions confer efficacy of enzalutamide in an in vivo bone tumor growth model.
    Semaan L; Mander N; Cher ML; Chinni SR
    BMC Cancer; 2019 Oct; 19(1):972. PubMed ID: 31638934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nuclear receptor ERRα and transcription factor ERG form a reciprocal loop in the regulation of TMPRSS2:ERG fusion gene in prostate cancer.
    Xu Z; Wang Y; Xiao ZG; Zou C; Zhang X; Wang Z; Wu D; Yu S; Chan FL
    Oncogene; 2018 Nov; 37(48):6259-6274. PubMed ID: 30042415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Highly specific targeting of the TMPRSS2/ERG fusion gene using liposomal nanovectors.
    Shao L; Tekedereli I; Wang J; Yuca E; Tsang S; Sood A; Lopez-Berestein G; Ozpolat B; Ittmann M
    Clin Cancer Res; 2012 Dec; 18(24):6648-57. PubMed ID: 23052253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.
    Hermans KG; van Marion R; van Dekken H; Jenster G; van Weerden WM; Trapman J
    Cancer Res; 2006 Nov; 66(22):10658-63. PubMed ID: 17108102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of NF-{kappa}B by TMPRSS2/ERG Fusion Isoforms through Toll-Like Receptor-4.
    Wang J; Cai Y; Shao LJ; Siddiqui J; Palanisamy N; Li R; Ren C; Ayala G; Ittmann M
    Cancer Res; 2011 Feb; 71(4):1325-33. PubMed ID: 21169414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of the TMPRSS2-ERG gene fusion in prostate cancer.
    Tomlins SA; Laxman B; Varambally S; Cao X; Yu J; Helgeson BE; Cao Q; Prensner JR; Rubin MA; Shah RB; Mehra R; Chinnaiyan AM
    Neoplasia; 2008 Feb; 10(2):177-88. PubMed ID: 18283340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 1{alpha},25-Dihydroxyvitamin D3 inhibits growth of VCaP prostate cancer cells despite inducing the growth-promoting TMPRSS2:ERG gene fusion.
    Washington MN; Weigel NL
    Endocrinology; 2010 Apr; 151(4):1409-17. PubMed ID: 20147525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inactivation of AR/TMPRSS2-ERG/Wnt signaling networks attenuates the aggressive behavior of prostate cancer cells.
    Li Y; Kong D; Wang Z; Ahmad A; Bao B; Padhye S; Sarkar FH
    Cancer Prev Res (Phila); 2011 Sep; 4(9):1495-506. PubMed ID: 21680704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castration-resistant prostate cancer.
    Cai C; Wang H; Xu Y; Chen S; Balk SP
    Cancer Res; 2009 Aug; 69(15):6027-32. PubMed ID: 19584279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abnormal expression of the ERG transcription factor in prostate cancer cells activates osteopontin.
    Flajollet S; Tian TV; Flourens A; Tomavo N; Villers A; Bonnelye E; Aubert S; Leroy X; Duterque-Coquillaud M
    Mol Cancer Res; 2011 Jul; 9(7):914-24. PubMed ID: 21669963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TMPRSS2:ERG gene fusion variants induce TGF-β signaling and epithelial to mesenchymal transition in human prostate cancer cells.
    Ratz L; Laible M; Kacprzyk LA; Wittig-Blaich SM; Tolstov Y; Duensing S; Altevogt P; Klauck SM; Sültmann H
    Oncotarget; 2017 Apr; 8(15):25115-25130. PubMed ID: 28445989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prostate cancer TMPRSS2:ERG fusion synergizes with the vitamin D receptor (VDR) to induce CYP24A1 expression-limiting VDR signaling.
    Kim JS; Roberts JM; Bingman WE; Shao L; Wang J; Ittmann MM; Weigel NL
    Endocrinology; 2014 Sep; 155(9):3262-73. PubMed ID: 24926821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural proteasome inhibitor celastrol suppresses androgen-independent prostate cancer progression by modulating apoptotic proteins and NF-kappaB.
    Dai Y; Desano J; Tang W; Meng X; Meng Y; Burstein E; Lawrence TS; Xu L
    PLoS One; 2010 Dec; 5(12):e14153. PubMed ID: 21170316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retigeric acid B exhibits antitumor activity through suppression of nuclear factor-κB signaling in prostate cancer cells in vitro and in vivo.
    Liu YQ; Hu XY; Lu T; Cheng YN; Young CY; Yuan HQ; Lou HX
    PLoS One; 2012; 7(5):e38000. PubMed ID: 22666431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the TMPRSS2/ERG fusion mRNA using liposomal nanovectors enhances docetaxel treatment in prostate cancer.
    Shao L; Kahraman N; Yan G; Wang J; Ozpolat B; Ittmann M
    Prostate; 2020 Jan; 80(1):65-73. PubMed ID: 31614005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TMPRSS2:ERG blocks neuroendocrine and luminal cell differentiation to maintain prostate cancer proliferation.
    Mounir Z; Lin F; Lin VG; Korn JM; Yu Y; Valdez R; Aina OH; Buchwalter G; Jaffe AB; Korpal M; Zhu P; Brown M; Cardiff RD; Rocnik JL; Yang Y; Pagliarini R
    Oncogene; 2015 Jul; 34(29):3815-25. PubMed ID: 25263440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of dutasteride in pre-clinical ETS fusion-positive prostate cancer models.
    Ateeq B; Vellaichamy A; Tomlins SA; Wang R; Cao Q; Lonigro RJ; Pienta KJ; Varambally S
    Prostate; 2012 Oct; 72(14):1542-9. PubMed ID: 22415461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.